Related Experiment Videos
Renal handling of beta-2-microglobulin in neonates treated with gentamicin
1University of Illinois, College of Medicine, Chicago.
Abstract:
Increased levels of urinary beta 2-microglobulin (beta 2M) have been used as a marker of proximal tubular dysfunction in human neonates. To assess the value of beta 2M in the detection of early stages of tubular damage caused by gentamicin, renal handling of beta 2M was studied sequentially in 18 gentamicin-treated neonates with idiopathic respiratory distress syndrome (mean birth weight 1,781 g, mean gestational age 33.7 weeks) during the first 7 days of life. These data were compared with those obtained from 10 control infants matched for gestational and postnatal ages. In addition, follow-up studies of renal function were conducted in 14 of 18 study infants 1 week after termination of therapy, on day 14 postpartum. The (+/- SD) fractional tubular excretion of beta 2M (FE beta 2M) tended to decrease significantly in the control infants from 10.3 +/- 1% on day 1 to 6.5 +/- 0.8% on day 7 postpartum (p less than 0.05). In infants treated with gentamicin, the mean FE beta 2M rose from 10.5 +/- 2% on day 1 to 17.1 +/- 1% on day 7 (p less than 0.01), followed by a decrease to 8.2 +/- 0.5% over the next 7 days (p less than 0.001). Compared with the control infants, values for the infants receiving gentamicin were significantly higher on postpartum days 3,5, and 7 (p less than 0.001). No significant differences in serum creatinine, creatinine clearance, or fractional tubular excretion of sodium were observed between the two groups during the study period.(ABSTRACT TRUNCATED AT 250 WORDS)
Insights
Urinary beta 2-microglobulin (beta 2M) indicates infant kidney damage. Gentamicin treatment in neonates significantly increased beta 2M levels, signaling early tubular dysfunction.
Area of Science:
- Neonatal Nephrology
- Pediatric Pharmacology
- Biomarker Research
Background:
- Urinary beta 2-microglobulin (beta 2M) is a recognized marker for proximal tubular dysfunction in neonates.
- Gentamicin is an antibiotic commonly used in neonates but can cause nephrotoxicity.
Purpose of the Study:
- To evaluate beta 2M as an early indicator of gentamicin-induced tubular damage in neonates.
- To assess the renal handling of beta 2M in gentamicin-treated infants compared to controls.
Main Methods:
- Sequential measurement of fractional tubular excretion of beta 2M (FE beta 2M) in 18 gentamicin-treated neonates and 10 controls.
- Comparison of FE beta 2M values during the first 7 days of life and follow-up at 14 days postpartum.
- Monitoring of serum creatinine, creatinine clearance, and fractional tubular excretion of sodium.
Main Results:
- FE beta 2M significantly increased in gentamicin-treated infants from day 1 (10.5%) to day 7 (17.1%), indicating tubular damage.
- Control infants showed a significant decrease in FE beta 2M over the same period.
- Elevated FE beta 2M in gentamicin group persisted on days 3, 5, and 7 compared to controls (p<0.001).
- No significant differences in serum creatinine, creatinine clearance, or sodium excretion were noted between groups.
Conclusions:
- Urinary beta 2M is a sensitive marker for detecting early proximal tubular dysfunction caused by gentamicin in neonates.
- Beta 2M excretion patterns can identify subclinical kidney injury before changes in creatinine levels are apparent.
- This finding supports the use of beta 2M monitoring in neonates receiving gentamicin therapy.